Albani 2020.

Study characteristics
Methods	Study design: prospective cohort NRS Type of publication: peer‐reviewed journal publication Setting and dates: hospital, 20 February 2020‐10 March 2020 Country: Italy Language: English Number of centres: 1 Trial registration number: NR
Participants	Number of participants: 1403 allocated (experimental = 799; comparator = 604), 27 excluded (1 < 18 years, 26 were still admitted to the hospital and, because of this, the discharge status was not available at time of analysis), 1376 analysed (experimental = 780; comparator = 596) Age, years (mean ± SD): 68.66 ± 12.62 (experimental), 70.6 ± 15.01 (comparator) Gender (male/female): 545/254 (experimental), 379/225 (comparator) Comorbidities (experimental/comparator): hypertension 35.9%/35.1%, diabetes 21.8%/19% Confounding factors: prior anticoagulation (experimental = 53, comparator = 13), surgery (NR), cancer (NR), antiplatelet use (NR), history of VTE (NR) Type of ventilator support: NR Inclusion criteria Admitted to the hospital Real time‐PCR from a nasopharyngeal swab or bronchoalveolar lavage resulted positive for SARS‐CoV‐2 Exclusion criteria Age < 18 years Being still admitted to hospital so that a definitive outcome was not available at the time of analysis
Interventions	Experimental: anticoagulation with enoxaparin 40‐80 mg/day, duration 3‐9 days Comparator: without anticoagulation Concomitant therapy: NR Duration of follow‐up: until death or hospital discharge
Outcomes	Primary outcomes Mortality Secondary outcomes Admission to ICU  Hospital length of stay PE VTE Acute myocardial infarction Cerebral infarction Haemorrhagic events
Notes	Sponsor/funding: quote "The authors received no specific funding for this work." COIs: quote "The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper." Protocol not available